Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bentsen's health stocks

Executive Summary

Democratic vice presidential candidate Lloyd Bentsen's financial disclosure statement, filed Aug. 15, lists assets and income from over a dozen drug and health care industry stocks, including income from Merck stock of between $ 15,000 and $ 50,000, the largest income contributor. The senator's most recent transactions in the drug industry, made within a month of the filing, were purchases of Johnson & Johnson and Schering common valued at $ 5,000-$ 15,000 and $ 5,000-$ 50,000, respectively. total value of Bentsen's income and asserts from drug and health care issues is at least $ 60,000. Because reporting rules require candidates only to list their holdings by value categories, the value of the senator's drug industry holdings could be well over $ 200,000. Among Bentsen's other drug issues are: Abbott, Lilly, Baxter, Squibb, and McKesson

Latest Headlines
See All
UsernamePublicRestriction

Register

PS014150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel